{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:50:39Z","timestamp":1790988639930,"version":"4.1.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,8,15]]},"abstract":"<jats:p>Established adverse prognostic factors in chronic lymphocytic leukemia (CLL) include CD38 expression, relative lack ofIgVH mutation, and defects of theTP53 gene. However, disruption of the p53 pathway can occur through mechanisms other than TP53 mutation, and we have recently developed a simple screening test that detects p53 dysfunction due to mutation of the genes encoding either p53 or ATM, a kinase that regulates p53. The present study was conducted to examine the predictive value of this test and to establish the relationship between p53 dysfunction, CD38 expression, and IgVHmutation. CLL cells from 71 patients were examined forIgVH mutation, CD38 expression, and p53 dysfunction (detected as an impaired p53\/p21 response to ionizing radiation). Survival data obtained from 69 patients were analyzed according to each of these parameters. Relative lack ofIgVH mutation (less than 5%; n\u2009=\u200945), CD38 positivity (antigen expressed on more than 20% of malignant cells; n\u2009=\u200919), and p53 dysfunction (n\u2009=\u200919) were independently confirmed as adverse prognostic factors. Intriguingly, all p53-dysfunctional patients and all but one of the CD38+ patients had greater than 5% IgVH mutation. Moreover, patients with p53 dysfunction and\/or CD38 positivity (n\u2009=\u200931) accounted for the short survival of the less mutated group. These findings indicate that the poor outcome associated with having less than 5%IgVH mutation may be due to the overrepresentation of high-risk patients with p53 dysfunction and\/or CD38 positivity within this group, and that CD38\u2212 patients with functionally intact p53 may have a prolonged survival regardless of the extent of IgVH mutation.<\/jats:p>","DOI":"10.1182\/blood-2001-11-0066","type":"journal-article","created":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T21:48:18Z","timestamp":1033508898000},"page":"1404-1409","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":182,"title":["Relationship between p53 dysfunction, CD38 expression, andIgVH mutation in chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"100","author":[{"given":"Ke","family":"Lin","sequence":"first","affiliation":[{"name":"From the Department of Haematology, Royal Liverpool University Hospital, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Sherrington","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, Royal Liverpool University Hospital, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dennis","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, Royal Liverpool University Hospital, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Matrai","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, Royal Liverpool University Hospital, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Cawley","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, Royal Liverpool University Hospital, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Pettitt","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, Royal Liverpool University Hospital, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021300243889300_B1","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJM199510193331606","article-title":"Chronic lymphocytic leukemia.","volume":"333","author":"Rozman","year":"1995","journal-title":"N Engl J Med."},{"key":"2020021300243889300_B2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.1999.17.1.399","article-title":"B-cell chronic lymphocytic leukemia: a bird of a different feather.","volume":"17","author":"Caligaris-Capio","year":"1999","journal-title":"J Clin Oncol."},{"key":"2020021300243889300_B3","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1172\/JCI3009","article-title":"Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.","volume":"102","author":"Fais","year":"1998","journal-title":"J Clin Invest."},{"key":"2020021300243889300_B4","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.","volume":"94","author":"Damle","year":"1999","journal-title":"Blood."},{"key":"2020021300243889300_B5","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated IgV(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood."},{"key":"2020021300243889300_B6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0167-5699(94)90148-1","article-title":"Human CD38: a glycoprotein in search of a function.","volume":"15","author":"Malavasi","year":"1994","journal-title":"Immunol Today."},{"key":"2020021300243889300_B7","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1182\/blood.V94.6.1837","article-title":"Mutational status of Ig VH genes provides clinically valuable information in B-cell chronic lymphocytic leukemia.","volume":"94","author":"Naylor","year":"1999","journal-title":"Blood."},{"key":"2020021300243889300_B8","first-page":"366a","article-title":"CD38 expression identifies two distinct subsets in B-chronic lymphocytic leukemia (B-CLL).","volume":"96(suppl 1)","author":"Del Poeta","year":"2000","journal-title":"Blood."},{"key":"2020021300243889300_B9","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1182\/blood.V97.6.1892","article-title":"CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia.","volume":"97","author":"Thunberg","year":"2001","journal-title":"Blood."},{"key":"2020021300243889300_B10","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1182\/blood.V97.6.1902","article-title":"CD38 expression and IgVH gene mutation in B-cell chronic lymphocytic leukemia.","volume":"97","author":"Matrai","year":"2001","journal-title":"Blood."},{"key":"2020021300243889300_B11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood.V98.1.181","article-title":"CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia.","volume":"98","author":"Ibrahim","year":"2001","journal-title":"Blood."},{"key":"2020021300243889300_B12","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1101\/gad.10.9.1054","article-title":"p53: puzzle and paradigm.","volume":"10","author":"Ko","year":"1996","journal-title":"Genes Dev."},{"key":"2020021300243889300_B13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0092-8674(00)81871-1","article-title":"p53, the cellular gatekeeper for growth and division.","volume":"88","author":"Levine","year":"1997","journal-title":"Cell."},{"key":"2020021300243889300_B14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/358015a0","article-title":"p53, guardian of the genome.","volume":"358","author":"Lane","year":"1992","journal-title":"Nature."},{"key":"2020021300243889300_B15","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/0092-8674(93)90719-7","article-title":"p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.","volume":"74","author":"Lowe","year":"1993","journal-title":"Cell."},{"key":"2020021300243889300_B16","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1046\/j.1365-2141.1999.01448.x","article-title":"Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms.","volume":"105","author":"Pettitt","year":"1999","journal-title":"Br J Haematol."},{"key":"2020021300243889300_B17","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1046\/j.1365-2141.1999.01649.x","article-title":"The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia.","volume":"106","author":"Pettitt","year":"1999","journal-title":"Br J Haematol."},{"key":"2020021300243889300_B18","first-page":"4187","article-title":"Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues.","volume":"60","author":"Pettitt","year":"2000","journal-title":"Cancer Res."},{"key":"2020021300243889300_B19","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood.V82.11.3452.3452","article-title":"p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1\/MDR3 gene expression.","volume":"82","author":"El Rouby","year":"1993","journal-title":"Blood."},{"key":"2020021300243889300_B20","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.V84.9.3148.3148","article-title":"p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies.","volume":"84","author":"Wattel","year":"1994","journal-title":"Blood."},{"key":"2020021300243889300_B21","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","article-title":"p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.","volume":"85","author":"Dohner","year":"1995","journal-title":"Blood."},{"key":"2020021300243889300_B22","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1182\/blood.V98.3.814","article-title":"p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation.","volume":"98","author":"Pettitt","year":"2001","journal-title":"Blood."},{"key":"2020021300243889300_B23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0140-6736(98)10117-4","article-title":"Inactivation of ataxia telangiectasia mutated gene in chronic lymphocytic leukaemia.","volume":"353","author":"Stankovic","year":"1999","journal-title":"Lancet."},{"key":"2020021300243889300_B24","first-page":"4552","article-title":"Deficiency of ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia.","volume":"58","author":"Starostik","year":"1998","journal-title":"Cancer Res."},{"key":"2020021300243889300_B25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0161-5890(92)90100-C","article-title":"Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire.","volume":"29","author":"Campbell","year":"1992","journal-title":"Mol Immunol."},{"key":"2020021300243889300_B26","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1093\/nar\/19.14.4008","article-title":"\u2018Touchdown\u2019 PCR to circumvent spurious priming during gene amplification.","volume":"19","author":"Don","year":"1991","journal-title":"Nucleic Acids Res."},{"key":"2020021300243889300_B27","volume-title":"V-BASE Sequence Directory. Cambridge","author":"Tomlinson","year":"1996"},{"key":"2020021300243889300_B28","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.V82.6.1820.1820","article-title":"bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia.","volume":"82","author":"Hanada","year":"1993","journal-title":"Blood."},{"key":"2020021300243889300_B29","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia.","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med."},{"key":"2020021300243889300_B30","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1126\/science.8235624","article-title":"Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38.","volume":"262","author":"Howard","year":"1993","journal-title":"Science."},{"key":"2020021300243889300_B31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0014-5793(93)80735-D","article-title":"Human CD38 catalyses the production of cyclic ADPribose.","volume":"335","author":"Summerhill","year":"1993","journal-title":"FEBS Lett."},{"key":"2020021300243889300_B32","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/eji.1830240532","article-title":"CD38 signaling by agonistic monoclonal antibody prevents apoptosis of human germinal center B cells.","volume":"24","author":"Zupo","year":"1994","journal-title":"Eur J Immunol."},{"key":"2020021300243889300_B33","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.4049\/jimmunol.151.6.3119","article-title":"B-lymphocyte surface molecule mediating activation and protection from apoptosis via calcium channels.","volume":"151","author":"Santos-Argumedo","year":"1993","journal-title":"J Immunol."},{"key":"2020021300243889300_B34","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1089\/107999099313299","article-title":"Upregulation of CD38 expression in leukemic B cells by interferon types I and II.","volume":"19","author":"Bauvois","year":"1999","journal-title":"J Interferon Cytokine Res."},{"key":"2020021300243889300_B35","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/ng0193-88","article-title":"Structure and physical map of 64 variable segments in the 3\u20320.8-megabase region of the human immunoglobulin heavy-chain locus.","volume":"3","author":"Matsuda","year":"1993","journal-title":"Nat Genet."},{"key":"2020021300243889300_B36","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1084\/jem.186.5.625","article-title":"Sites of B lymphocyte selection, activation and tolerance in spleen.","volume":"186","author":"Liu","year":"1997","journal-title":"J Exp Med."},{"key":"2020021300243889300_B37","doi-asserted-by":"crossref","first-page":"820","DOI":"10.4049\/jimmunol.160.2.820","article-title":"Lack of intraclonal diversification in Ig heavy and light chain genes expressed by CD5+ IgM+ chronic lymphocytic leukemia B cells: a multiple time point analysis.","volume":"160","author":"Schettino","year":"1998","journal-title":"J Immunol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/4\/1404\/1686292\/h81602001404.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/4\/1404\/1686292\/h81602001404.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T19:38:01Z","timestamp":1682365081000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/100\/4\/1404\/106228\/Relationship-between-p53-dysfunction-CD38"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8,15]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,8,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2001-11-0066","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,8,15]]}}}